Patient Leaflet Updated 06-Jan-2025 | Sanofi Pasteur
Stamaril
STAMARIL® Powder and solvent for suspension for injection in pre-filled syringe
Yellow fever vaccine (Live)
1. What STAMARIL is and what it is used for
2. What you need to know before you or your child use STAMARIL
3. How to use STAMARIL
4. Possible side effects
5. How to store STAMARIL
6. Contents of the pack and other information
STAMARIL is a vaccine that provides protection against a serious infectious disease called yellow fever.
Yellow fever occurs in certain areas of the world and is spread to man through the bites of infected mosquitoes.
STAMARIL is given to people who:
To obtain a valid vaccination certificate against yellow fever, it is necessary to be vaccinated in an approved vaccination centre by a qualified and trained healthcare professional so that an International Certificate of Vaccination can be issued. This certificate is valid from 10 days after the first dose of vaccine. In some circumstances, when a booster is needed, the certificate (see Section 3) is valid immediately after the injection.
It is important to tell your healthcare professional if any of the points below apply to you or your child. If there is anything you do not understand, ask your healthcare professional to explain.
Before using Stamaril, it is important that you complete a risk assessment with a trained healthcare professional, to determine whether you should receive the vaccine.
As with all vaccines, STAMARIL may not fully protect all persons who are vaccinated.
Fainting can occur following, or even before, any needle injection. Therefore tell your healthcare professional if you or your child fainted with a previous injection.
Tell your healthcare professional if you are taking, have recently taken or might take any other medicines.
If you have recently had any treatment or medicine which may have weakened your immune system, the vaccination must be delayed until your laboratory results show that your immune system has recovered. Your doctor will advise you when it is safe for you to be vaccinated.
STAMARIL can be given at the same time as measles vaccine or vaccines against typhoid fever (those containing the Vi capsular polysaccharide) and/ or hepatitis A.
Vaccination with STAMARIL may lead to false positive results of blood tests for dengue or Japanese encephalitis. If you or your child have in the future such tests prescribed, please inform your doctor about this vaccination.
If you are pregnant, or breastfeeding, think you may be pregnant or are planning to have a baby, ask your healthcare professional for advice before being vaccinated.
You should not receive STAMARIL during pregnancy or breastfeeding unless this cannot be avoided. Also, it is recommended that you do not become pregnant within one month after receiving STAMARIL. Your healthcare professional can advise you on whether it is essential that you are vaccinated. In case vaccination is needed, it is recommended to interrupt breastfeeding for at least 2 weeks after you receive STAMARIL. In case you receive the vaccine while pregnant or breastfeeding, consult your healthcare professional.
This medicine contains less than 1 mmol sodium (23 mg) per dose that is to say essentially “sodium free”, and less than 1 mmol potassium (39 mg) per dose that is to say essentially “potassium free”.
This medicine contains approximately 8 mg of sorbitol per dose.
STAMARIL is given as a single, 0.5 millilitre dose to adults and children from 6 months of age.
The first dose should be given at least 10 days before protection from yellow fever is needed. This is because it takes 10 days for the first dose of vaccine to work and provide good protection against the yellow fever virus. The protection provided by this dose is expected to last at least 10 years and may be life-long.
In some circumstances, a booster with one dose (0.5 millilitre) may be needed:
STAMARIL is given as an injection by a qualified and trained healthcare professional. It is usually injected just underneath the skin but it can be given into a muscle.
It must not be injected into a blood vessel.
In some cases, more than the recommended dose was used.
In these cases, when side effects were reported, they were in line with those described in Section 4.
If you have any further questions on the use of this vaccine, ask your healthcare professional.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
The following serious side effects have sometimes been reported:
Allergic reactions:
Reactions affecting the brain and nerves:
These may occur within one month of the vaccination and have sometimes been fatal.
Symptoms may include:
Serious reaction affecting vital organs:
This may occur within 10 days of the vaccination and may have a fatal outcome. The reaction can resemble an infection with the yellow fever virus. It generally begins with feeling tired, fever, headache, muscle pain and sometimes low blood pressure. It may then go on to a severe muscle and liver disorder, drops in number of some types of blood cells resulting in unusual bruising or bleeding and increased risk of infections, and loss of normal functioning of the kidneys and lungs.
If you experience ANY of the above symptoms after vaccination, seek medical attention IMMEDIATELY mentioning that you have recently received STAMARIL.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
Very common (may affect more than 1 in 10 people)
These side effects usually occurred within the 3 days following vaccination and lasted usually not more than 3 days. Most of these side effects were of mild intensity.
If you get any side effects, talk to your healthcare professional. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.
By reporting side effects you can help provide more information on the safety of this medicine.
After reconstitution, for one dose (0.5 mL):
STAMARIL is presented as a powder and solvent for suspension for injection (powder in a vial (0.5 mL dose) + solvent in a pre-filled syringe (0.5 mL dose) with or without needle). Pack size 1, 10, 20.
After reconstitution the suspension is beige to pink beige, more or less opalescent.
Not all pack sizes may be marketed.
This medicinal product is authorised in the Member States of the EEA under the following name:
STAMARIL: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hrvatska, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Poland, Portugal, Romania, Slovakia, Spain, Sweden, The Netherlands, United Kingdom, Iceland, Norway.
This leaflet was last revised in 11/2024
Other sources of information
Detailed information on this medicine is available on the website of the Medicines and Healthcare Products Regulatory Agency (MHRA).
105 N DRAFT 1052
410, Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
+44 (0)800 035 2525